HC Wainwright Boosts Atossa Therapeutics (NASDAQ:ATOS) Price Target to $7.00

Atossa Therapeutics (NASDAQ:ATOS) had its target price lifted by research analysts at HC Wainwright from $6.00 to $7.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 410.95% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Ascendiant Capital Markets raised their target price on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 8th.

Atossa Therapeutics Price Performance

Shares of ATOS stock opened at $1.37 on Wednesday. The stock’s 50-day moving average price is $1.44 and its 200 day moving average price is $1.38. The stock has a market capitalization of $172.29 million, a PE ratio of -6.23 and a beta of 1.23. Atossa Therapeutics has a 52-week low of $0.63 and a 52-week high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS) last released its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. Analysts expect that Atossa Therapeutics will post -0.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atossa Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its holdings in shares of Atossa Therapeutics by 3,160.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Atossa Therapeutics by 11.9% in the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after buying an additional 164,540 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Atossa Therapeutics during the 2nd quarter valued at approximately $161,000. Virtu Financial LLC purchased a new stake in shares of Atossa Therapeutics during the 1st quarter worth approximately $151,000. Finally, Vanguard Group Inc. grew its holdings in shares of Atossa Therapeutics by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after acquiring an additional 78,269 shares during the period. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.